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Objective. This 24-week, phase IIb, double-blind
study was undertaken to evaluate the efficacy and safety
of mavrilimumab (a monoclonal antibody to granulo-
cyte–macrophage colony-stimulating factor receptor a)
and golimumab (a monoclonal antibody to tumor necro-
sis factor [anti-TNF]) in patients with rheumatoid
arthritis (RA) who have had an inadequate response to
disease-modifying antirheumatic drugs (DMARDs) (re-
ferred to as DMARD-IR) and/or inadequate response to
other anti-TNF agents (referred to as anti-TNF–IR).
Methods. Patients with active RA and a history
of DMARD-IR (≥1 failed regimen) or DMARD-IR (≥1
failed regimen) and anti-TNF–IR (1–2 failed regimens)
were randomized 1:1 to receive either mavrilimumab
100 mg subcutaneously every other week or golimumab
50 mg subcutaneously every 4 weeks alternating with
placebo every 4 weeks, administered concomitantly with
methotrexate. The primary end points were the American
College of Rheumatology 20% improvement (ACR20),
50% improvement, and 70% improvement response rates
at week 24, percentage of patients achieving a Disease
Activity Score in 28 joints using C-reactive protein level
(DAS28-CRP) of <2.6 at week 24, percentage of patients
with a score improvement of >0.22 on the Health Assess-
ment Questionnaire (HAQ) disability index (DI) at week
24, and safety/tolerability measures. This study was not
powered to formally compare the 2 treatments.
Results. At week 24, differences in the ACR20,
ACR50, and ACR70 response rates between the mavrili-
mumab treatment group (n = 70) and golimumab treat-
ment group (n = 68) were as follows: in all patients,
3.5% (90% confidence interval [90% CI] 16.8, 9.8),
8.6% (90% CI 22.0, 4.8), and 9.8% (90% CI 21.1,
1.4), respectively; in the anti-TNF–IR group, 11.1%
(90% CI 7.8, 29.9), 8.7% (90% CI 28.1, 10.7), and
0.7% (90% CI 18.0, 16.7), respectively. Differences in
the percentage of patients achieving a DAS28-CRP of
<2.6 at week 24 between the mavrilimumab and goli-
mumab groups were 11.6% (90% CI 23.2, 0.0) in all
patients, and 4.0% (90% CI 20.9, 12.9) in the anti-
TNF–IR group. The percentage of patients achieving a
>0.22 improvement in the HAQ DI score at week 24
was similar between the treatment groups. Treatment-
emergent adverse events were reported in 51.4% of
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mavrilimumab-treated patients and 42.6% of goli-
mumab-treated patients. No deaths were reported, and
no specific safety signals were identified.
Conclusion. The findings of this study demon-
strate the clinical efficacy of both treatments, mavrili-
mumab at a dosage of 100 mg every other week and
golimumab at a dosage of 50 mg every 4 weeks, in
patients with RA. Both regimens were well-tolerated in
patients who had shown an inadequate response to
DMARDs and/or other anti-TNF agents.
Granulocyte–macrophage colony-stimulating fac-
tor (GM-CSF) is a proinflammatory cytokine that plays a
central role in rheumatoid arthritis (RA) pathogenesis
through its effects on the activation, differentiation, and
survival of macrophages, dendritic cells, and neutrophils
(1–4). This knowledge, taken together with the observa-
tion that GM-CSF and its receptor, GM-CSFRa, are up-
regulated in synovial tissue and circulating mononuclear
cells from patients with RA (5–7), supports targeting of
the GM-CSF pathway as a potential therapeutic appro-
ach. Mavrilimumab, a fully human monoclonal antibody
that targets GM-CSFRa, is designed to modulate the
activation, differentiation, and survival of macrophages
and neutrophils, thereby reducing cell numbers in inflam-
matory lesions (8). The efficacy of mavrilimumab has pre-
viously been demonstrated and was well-tolerated in
patients with RA who have had an inadequate response
to disease-modifying antirheumatic drugs (DMARDs)
(9–11) (herein referred to as DMARD-IR). However,
mavrilimumab has not been evaluated in patients with
RA who have had an inadequate response to anti–tumor
necrosis factor (anti-TNF) agents (herein referred to as
anti-TNF–IR).
The use of TNF antagonists in RA has substan-
tially improved outcomes in patients (12). However,
analysis of the Consortium of Rheumatology Research-
ers of North America registry, a database of North Amer-
ican RA patients, indicates that 80% of patients do not
achieve a Disease Activity Score in 28 joints using ery-
throcyte sedimentation rate (DAS28-ESR) of <2.6 (13)
within 12 months of initiating anti-TNF treatment (14).
Therapies targeting other mechanisms involved in the
pathogenesis of RA (inhibition of T cell costimulation
[abatacept]; the B cell–restricted surface antigen CD20
[rituximab]; the interleukin-6 receptor [tocilizumab]; and
JAK kinase [tofacitinib]) are also beneficial (15,16).
Nonetheless, ~30–40% of patients receiving treatment
with an approved biologic agent do not achieve a 20%
improvement response based on the American College
of Rheumatology improvement response criteria
(ACR20) (17–19), highlighting a continued unmet need
for therapies with an alternative mechanism of action.
Against this background, GM-CSF inhibition is a
plausible and novel potential option for the management
of RA. In this phase IIb study, we sought to evaluate the
efficacy and safety of mavrilimumab in patients with a
history of DMARD-IR and anti-TNF–IR. The study inclu-
ded a detailed assessment of patients’ pulmonary function,
because inhibition of GM-CSF signaling by mavrilimumab
has the potential to affect the clearance of surfactant by
alveolar macrophages; anti–GM-CSF autoantibodies are
responsible for ~90% of cases of pulmonary alveolar pro-
teinosis, a rare disease resulting from the accumulation of
lung surfactant due to the development of autoantibodies
that inhibit GM-CSF signaling (20,21). For contextual rele-
vance, we included a parallel treatment arm in which a
TNF antagonist, golimumab, was evaulated. Direct com-
parison of these agents will form the basis of a dedicated
biomarker program, enabling the elucidation of differential
mechanisms of action for these agents, each of which tar-
gets different mediators of inflammation.
PATIENTS AND METHODS
Study design. The study was designed as a phase II mul-
ticenter, exploratory, double-blind, randomized, parallel-group
study in patients with RA (known as EARTH EXPLORER 2),
conducted in accordance with the principles of the Declaration
of Helsinki and the International Conference on Harmonisation
Guidelines for Good Clinical Practice. It was approved by the
appropriate institutional review boards or independent ethics
committees at each site. All patients provided written informed
consent.
Patients ages 18–80 years with adult-onset RA who had
at least moderately active disease, defined as a DAS28 using
C-reactive protein (DAS28-CRP) of ≥3.2 at screening and a
DAS28-ESR of ≥3.2 on day 1, and who had at least 4 swollen
joints at screening and on day 1 and were considered to have a
history of either DMARD-IR (≥1 failed regimen) or
DMARD-IR (≥1 failed regimen) and anti-TNF–IR (1–2 failed
regimens; excluding golimumab) were enrolled. Patients who
experienced treatment failure with a TNF antagonist were
defined as those who had experienced an inadequate response,
safety issue, or intolerance to 1 or 2 anti-TNF agents other
than golimumab, given for at least 3 months, with the last dose
having been administered at least 8 weeks prior to the first
study dose. Key exclusion criteria included a history of, or cur-
rent presence of, inflammatory joint disease or other systemic
autoimmune disorder other than RA. In addition, patients
were excluded if they had ever received biologic therapies
(other than a TNF antagonist) for RA or had received sul-
fasalazine, azathioprine, cyclosporine, or D-penicillamine within
≤28 days of day 1 and leflunomide ≤12 weeks before day 1.
Patients were randomized using an interactive voice
recognition system/interactive web recognition system (IVRS/
IWRS), which proceeded once the investigators had con-
firmed the patients’ eligibility for the study. Patients were
randomized (by IVRS/IWRS) in a 1:1 ratio to receive either
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mavrilimumab subcutaneously (SC) 100 mg every other week
or golimumab SC 50 mg every 4 weeks (starting at week 0)
alternating with placebo every 4 weeks (starting at week 2;
used to maintain the treatment blind), for 24 weeks. Ran-
domization was performed in an equal ratio across the treat-
ment arms and stratified by number of prior anti-TNF
failures (0, 1, or 2). Patients in the DMARD-IR group were
in the anti-TNF stratum of 0.
The choice of mavrilimumab dosage was based on
previous efficacy and safety data from a phase IIa study (9)
in which mavrilimumab 100 mg every other week was used as
the largest dosage, as supported by pharmacokinetic/pharma-
codynamic modeling of the same data. There were no data
available on mavrilimumab dosages of >100 mg every other
week at the time that this study was initiated. Therefore,
mavrilimumab 100 mg every other week was selected. The
golimumab dosage selected for this study (50 mg SC every 4
weeks) was based on the approved dosage recommended in
the prescribing information.
All patients received their randomized study drug for
24 weeks concomitantly with a stable dosage of methotrexate
(7.5–25 mg/week). For their dosage to be considered stable,
patients should have received the same dosage of methotrexate
for at least 4 weeks before screening. Stable dosages of oral
corticosteroids (prednisone ≤7.5 mg/day), analgesics, and non-
steroidal antiinflammatory drugs were permitted during the
course of the study. After week 12, patients who had not
responded adequately to the blinded study treatment (defined
as <20% improvement in both the swollen joint count and the
tender joint count compared with day 1) were eligible to enter
an open-label extension (OLE) study (ClinicalTrials.gov identi-
fier 01712399). After week 24, all patients were eligible for
screening to enter the long-term OLE study.
The primary population for efficacy analyses was the
modified intent-to-treat (mITT) population, including all ran-
domized patients who had received any study drug. The safety
population included all patients who had received any study
drug and had safety data available.
Efficacy assessments. The primary efficacy end points
were the ACR20 improvement response rate as well as the
50% and 70% improvement response rates at week 24, the
percentage of patients with a DAS28-CRP of <2.6 at week
24, and the percentage of patients with a score improvement
of >0.22 in the Health Assessment Questionnaire (HAQ)
disability index (DI) (22) at week 24.
Secondary efficacy end points (assessed at weeks 1, 2, 4,
8, 12, 16, 20, and 24) included the following: change from base-
line in the DAS28-CRP, percentage of patients with a European
League Against Rheumatism improvement response (23) based
on the DAS28-CRP, percentage of patients with a DAS28-CRP
of <3.2, percentage of patients with a DAS28-ESR of <2.6, the
ACR20, ACR50, and ACR70 response rates, change from base-
line in the CRP and ESR, response rates based on achievement
of a Clinical Disease Activity Index (CDAI) score of ≤2.8 (24),
and response rates based on achievement of a Simplified
Disease Activity Index (SDAI) score of ≤3.3 (25).
Immunogenicity assessments. The immunogenicity
potential of mavrilimumab (measured as the presence of any
antidrug antibody response) was determined using a validated
electrochemiluminescence method. Serum samples for deter-
mination of the antidrug antibody response were obtained
predose on day 1, and at weeks 0, 4, 12, 20, and 24.
Safety assessments. Adverse events (AEs) and seri-
ous AEs (SAEs) were graded by investigators according to
their severity and relationship to the study drug. In addition,
investigators assessed the relationship between SAEs and
protocol procedures. Laboratory measurements, vital signs,
pulmonary safety tests (including spirometry, testing for dif-
fusing capacity for carbon monoxide of the lung, chest
radiography, and dyspnea score), and the change from base-
line scores were summarized by treatment group and time
point. Adjudication of lung function abnormalities and pul-
monary AEs, to identify potential cases of pulmonary alveo-
lar proteinosis, was performed by an independent pulmonary
expert committee whose members were blinded with regard
to the treatment group.
Figure 1. Disposition of patients in the randomized phase IIb study of the efficacy and safety of mavrilimumab and golimumab in patients with
rheumatoid arthritis. DMARD-IR = inadequate response to disease-modifying antirheumatic drugs; anti-TNF–IR = inadequate response to anti–
tumor necrosis factor agents; Q4W = every 4 weeks; eow = every other week; AE = adverse event.
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Statistical analysis. The sample size was selected to
estimate the difference between the mavrilimumab and
golimumab treatment groups with a stated degree of accuracy.
It was not selected to detect differences with statistical
significance (and no power analyses were carried out). With
a sample size of 60 patients per treatment group, the
difference between the upper limit of the 90% confidence
interval (90% CI) and the estimate of the treatment differ-
ence ranged between 9% and 15% for the primary end
points. For each of the primary end points, responses were
analyzed by applying a test of treatment difference in the
proportion of responders, using logistic regression. The
number of TNF antagonist failures was used as a categorical
covariate, and results were reported with 2-sided 90% CIs;
the standard error of the difference in proportions was
estimated using the delta method (26). Patients who with-
drew from treatment for any reason (including entering the
OLE), those who started a new medication for RA, or those
for whom the methotrexate dosage was increased were
imputed as nonresponders for all subsequent assessments.
AE and other safety data were summarized with descriptive
statistics.
RESULTS
Demographic and baseline clinical characteristics
of the patients. The study was conducted at 36 sites in 13
European and South American countries, with patients
randomized and evaluated between March 2013 (first
patient randomized) and February 2015 (last patient, last
visit). In total, 215 patients were screened, with 138 ran-
domized to 1 of the 2 treatment groups (68 to receive
golimumab, 70 to receive mavrilimumab); 14 patients dis-
continued treatment (3 in the golimumab group, 11 in the
mavrilimumab group), and 124 patients (89.9%) com-
pleted the study (Figure 1). All randomized patients were
included in both the mITTand safety populations.
Baseline demographics and disease characteris-
tics were similar between the treatment groups
(Table 1), with the following exceptions: for patients in
the mavrilimumab treatment group compared with the
golimumab group, disease duration was shorter (5.8
years versus 7.6 years) and the baseline CRP concen-
tration was higher (8.3 mg/liter versus 6.5 mg/liter).
Across both treatment groups, a higher level of disease
activity was observed at baseline in the anti-TNF–IR
stratum compared with the DMARD-IR population, in
terms of longer duration of RA, more frequent use of
corticosteroids, higher disease activity according to the
DAS28-CRP, a higher baseline HAQ DI score, and
higher baseline concentrations of CRP. An imbalance
in regional distribution of recruitment between the 2
strata was noted, with more patients in the anti-TNF–IR
stratum than in the DMARD-IR stratum recruited in
South America (~56% versus ~11%).
Efficacy. Overall population (week 24). At week 24,
ACR20, ACR50, and ACR70 improvement responses in
disease activity were observed in 62.0%, 34.8%, and
16.1% of patients, respectively, among those receiving
mavrilimumab 100 mg every other week, compared with
65.6%, 43.4%, and 25.9% of patients, respectively, among
those receiving golimumab 50 mg every 4 weeks. Differ-
ences in the ACR20, ACR50, and ACR70 response rates
between the mavrilimumab and golimumab treatment
groups were3.5% (90% CI 16.8, 9.8), 8.6% (90% CI
22.0, 4.8), and 9.8% (90% CI21.1, 1.4), respectively.
A DAS28-CRP of <2.6 was achieved at week 24 by
17.4% of the mavrilimumab-treated patients and 29.0%
of the golimumab-treated patients, with a difference
between treatment groups of 11.6% (90% CI 23.2,
0.0). Evidence of low disease activity (a DAS28-CRP of
<3.2) at week 24 was observed in 28.9% of the mavrili-
mumab-treated patients and 40.6% of the golimumab-
treated patients. A higher percentage of patients in the
golimumab treatment group (69.0%) than in the mavrili-
mumab treatment group (58.7%) were classified as
responders (HAQ DI score improvement of >0.22) (27);
the difference in the HAQ DI response between the 2
treatment groups was 10.3% (90% CI 23.7, 3.0). The
mean  SEM change from baseline in the HAQ DI score
was 0.44  0.07 in the mavrilimumab group and 0.64
 0.07 in the golimumab group.
The percentages of patients with a CDAI score
of ≤2.8 at week 24 were 5.7% among those receiving
mavrilimumab 100 mg every other week and 17.6%
among those receiving golimumab 50 mg every 4
weeks. An SDAI score of ≤3.3 was reported in 7.2% of
patients receiving mavrilimumab and 18.9% of those
receiving golimumab.
Although treatment differences in the ACR20
response rate and the DAS28-CRP were consistent within
regions, differences in response rates were observed
between the geographic regions of Europe and South
America, irrespective of the drug allocation and stratum.
For example, higher response rates were observed in
patients from South America compared with those from
Europe, both in the mavrilimumab treatment group
(ACR20 response rate, 78.3% versus 53.2%; adjusted
change in the DAS28-CRP, mean  SEM 2.47  0.298
versus 1.30  0.272) and in the golimumab treatment
group (ACR20 response rate, 85.0% versus 58.3%;
adjusted change in the DAS28-CRP, mean  SEM 2.86
 0.315 versus 1.56  0.275).
Anti-TNF–IR population (week 24). Of the patients
within the anti-TNF–IR group (n = 63), the percentage
achieving an ACR20 response at week 24 was 72.3% (22
of 31 patients) in the mavrilimumab treatment group
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compared with 61.2% (20 of 32 patients) in the
golimumab treatment group (Figure 2A), a difference of
11.1% (90% CI 7.8, 29.9). The percentage of ACR50 or
ACR70 responders was similar between treatment groups,
with a difference between the mavrilimumab and
golimumab treatment groups of 8.7% (90% CI 28.1,
10.7) for the ACR50 response rate and 0.7% (90% CI
18.0, 16.7) for the ACR70 response rate (Figure 2A).
Similarly, the percentages of patients achieving a DAS28-
CRP of <2.6, improvement in the HAQ DI score of >0.22,
and a DAS28-CRP of <3.2 at week 24 were similar
between the treatment groups (Figures 2BD).
Table 1. Demographic and baseline clinical characteristics of the patients with rheumatoid arthritis (RA)*
Anti-TNF–IR DMARD-IR Overall population
Mavrilimumab
100 mg
every other week
(n = 31)
Golimumab
50 mg
every 4 weeks
(n = 32)
Mavrilimumab
100 mg
every other week
(n = 39)
Golimumab
50 mg
every 4 weeks
(n = 36)
Mavrilimumab
100 mg
every other week
(n = 70)
Golimumab
50 mg
every 4 weeks
(n = 68)
Demographics
Age, mean  SD years 50.2  13.3 46.9  10.5 50.2  13.3 52.5  11.8 50.2  13.3 49.9  11.4
Female, no. (%) 28 (90.3) 28 (87.5) 28 (71.8) 29 (80.6) 56 (80.0) 57 (83.8)
Race, no. (%)
White 26 (83.9) 25 (78.1) 36 (92.3) 32 (88.9) 62 (88.6) 57 (83.8)
American Indian or native Alaskan 5 (16.1) 7 (21.9) 2 (5.1) 2 (5.6) 7 (10.0) 9 (13.2)
Asian 0 (0.0) 0 (0.0) 1 (2.6) 1 (2.8) 1 (1.4) 1 (1.5)
Black or African American 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.8) 0 (0.0) 1 (1.5)
Region of enrollment, no. (%)
Europe 12 (38.7) 16 (50.0) 35 (89.7) 32 (88.9) 47 (67.1) 48 (70.6)
South America 19 (61.3) 16 (50.0) 4 (10.3) 4 (11.1) 23 (32.9) 20 (29.4)
Weight, mean  SD kg 72.9  14.3 76.3  17.4 73.1  17.3 74.0  19.1 73.0  16.0 75.1  18.8
Body mass index, mean  SD kg/m2 28.2  5.5 29.2  5.4 26.6  2.2 26.5  5.1 27.3  5.3 27.8  5.4
Baseline clinical characteristics
Duration of RA, median years 6.0 8.4 5.4 6.8 5.8 7.6
Methotrexate use
Total no. (%) 31 (100) 32 (100) 39 (100) 36 (100) 70 (100) 68 (100)
Dosage, mean  SD mg/week 15.9  3.8 14.1  3.7 15.5  4.1 15.3  3.9 15.6  4.0 14.7  3.8
<12.5 mg/week, no. (%) 3 (9.7) 10 (31.3) 7 (17.9) 5 (13.9) 10 (14.3) 15 (22.1)
≥12.5<20 mg/week, no. (%) 21 (67.7) 19 (59.4) 22 (56.4) 24 (66.7) 43 (61.4) 43 (63.2)
≥20–25 mg/week, no. (%) 7 (22.6) 3 (9.4) 10 (25.6) 7 (19.4) 17 (24.3) 10 (14.7)
Corticosteroid use
Total no. (%) 22 (71.0) 22 (68.8) 19 (48.7) 18 (50.0) 41 (58.6) 40 (58.8)
Dosage, mean  SD mg/day 5.4  1.2 4.8  1.7 5.3  1.2 5.4  1.0 5.4  1.1 5.1  1.5
<5 mg/day, no. (%) 0 (0.0) 3 (13.6) 1 (5.3) 0 (0.0) 1 (2.4) 3 (7.5)
≥5 mg/day, no. (%) 22 (100) 19 (86.4) 18 (94.7) 18 (100) 40 (97.6) 37 (92.5)
Previous anti-TNF failures, no. (%)
0 (DMARD-IR population) 0 (0.0) 0 (0.0) 39 (100) 36 (100) 39 (55.7) 36 (52.9)
1 (anti-TNF–IR population) 27 (87.1) 30 (93.8) 0 (0.0) 0 (0.0) 27 (38.6) 30 (44.1)
2 (anti-TNF–IR population) 4 (12.9) 2 (6.3) 0 (0.0) 0 (0.0) 4 (5.7) 2 (2.9)
Anti-TNF failure, no. (%)†
Adalimumab 13 (41.9) 7 (21.9) 0 (0.0) 0 (0.0) 13 (18.6) 7 (10.3)
Certolizumab pegol 7 (22.6) 7 (21.9) 0 (0.0) 0 (0.0) 7 (10.0) 7 (10.3)
Etanercept 10 (32.3) 15 (46.9) 0 (0.0) 0 (0.0) 10 (14.3) 15 (22.1)
Infliximab 5 (16.1) 6 (18.8) 0 (0.0) 0 (0.0) 5 (7.1) 6 (8.8)
Rheumatoid factor–positive, no. (%) 24 (77.4) 24 (75.0) 29 (74.4) 29 (80.6) 53 (75.7) 53 (77.9)
ACPA-positive, no. (%) 23 (74.2) 22 (68.8) 24 (61.5) 30 (83.3) 47 (67.1) 52 (76.5)
DAS28-CRP, mean  SD 6.1  0.8 6.0  0.6 5.6  1.1 5.5  0.9 5.8  1.0 5.7  0.8
DAS28-ESR, mean  SD 6.8  0.7 6.8  0.6 6.4  1.0 6.3  0.9 6.6  0.9 6.5  0.8
HAQ DI score, mean  SD 1.9  0.5 1.8  0.5 1.4  0.6 1.4  0.5 1.6  0.6 1.6  0.5
Swollen joint count, mean  SD 16.1  8.4 16.2  7.1 12.5  4.9 12.9  5.4 14.1  6.9 14.5  6.4
Tender joint count, mean  SD 25.9  13.6 28.9  14.6 24.4  12.4 21.4  12.1 25.0  12.9 24.9  13.7
Geometric mean CRP, mg/liter 10.9 7.0 6.7 6.1 8.3 6.5
Geometric mean ESR, mm/hour 39.9 38.6 36.2 35.5 37.8 36.9
* Anti-TNF–IR = inadequate response to anti–tumor necrosis factor agents; DMARD-IR = inadequate response to disease-modifying antirheu-
matic drugs; ACPA = anti–citrullinated protein antibody; DAS28-CRP = Disease Activity Score in 28 joints using C-reactive protein level; DAS28-
ESR = DAS28 using erythrocyte sedimentation rate; HAQ DI = Health Assessment Questionnaire disability index.
† The prior anti-TNF treatment had failed because there was a lack of initial efficacy (n = 14) or loss of efficacy (n = 48), the medication was
given only in the clinical study (n = 1), or an adverse event occurred (n = 3). Some patients had previously experienced treatment failure with 2
anti-TNF agents; if the reasons for failure were different for the 2 TNFs, both reasons were included.
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At week 24 in the anti-TNF–IR population,
the adjusted change from baseline in the DAS28-CRP
was a mean  SEM –1.99  0.3 in those receiving
mavrilimumab 100 mg every other week compared with
–2.24  0.3 in those receiving golimumab 50 mg every 4
weeks, with a difference between the mavrilimumab and
golimumab groups of 4.0% (90% CI 20.9, 12.9). The
percentage of patients with a CDAI score of ≤2.8 at week
24 was 6.7% in the mavrilimumab 100 mg every other
week group compared with 9.0% in the golimumab 50 mg
every 4 weeks group. An SDAI score of ≤3.3 was achieved
at week 24 by 10.1% of mavrilimumab-treated patients
and 12.1% of golimumab-treated patients.
Of the 6 patients who had previously experienced
treatment failure with 2 TNF antagonists, an ACR20
improvement response was achieved by 2 of the 3
patients treated with mavrilimumab. In contrast, none of
the 3 patients treated with golimumab achieved an
ACR20 response.
DMARD-IR population (week 24). The ACR20,
ACR50, and ACR70 response rates, the percentage of
patients achieving a HAQ DI score improvement of >0.22
(27), and the percentage of patients achieving a DAS28-
CRP of <2.6 and DAS28-CRP of <3.2 at week 24 in the
DMARD-IR stratum are shown in Figures 3A–D. Differ-
ences in the ACR20, ACR50, and ACR70 response rates
between the mavrilimumab-treated patients and the
golimumab-treated patients were 15.6% (90% CI
33.8, 2.6), 8.5% (90% CI 27.1, 10.0), and 17.5%
(90% CI 32.2, 2.9), respectively. The adjusted change
from baseline in the DAS28-CRP was a mean  SEM
–1.89 0.2 in those receiving mavrilimumab 100 mg every
other week compared with –2.27  0.2 in those receiving
golimumab 50 mg every 4 weeks, with a difference
between the mavrilimumab-treated and golimumab-
treated patients of 17.9% (90% CI 34.0, 1.9).
Response rates based on achievement of a
CDAI score of ≤2.8 at week 24 in the DMARD-IR
Figure 2. Response to mavrilimumab compared to golimumab over 24 weeks of treatment in patients with a history of an inadequate response to anti–tu-
mor necrosis factor agents. Responses were measured based on the percentage of patients with a response according to the American College of Rheuma-
tology criteria for 20% improvement (ACR20), 50% improvement, and 70% improvement (A), the percentage of patients with a Disease Activity Score in
28 joints using C-reactive protein level (DAS28-CRP) of <2.6 (B), the percentage of patients with a score improvement of >0.22 on the Health Assessment
Questionnaire (HAQ) disability index (DI) (C), and the percentage of patients with a DAS28-CRP of <3.2 (D). Results are shown as the mean  SEM.
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stratum were 5.1% in the mavrilimumab 100 mg every
other week group and 25.0% in the golimumab 50 mg
every 4 weeks group. The percentage of patients with
an SDAI of ≤3.3 at week 24 was 5.1% among patients
treated with mavrilimumab and 25.0% among those
treated with golimumab.
Disease markers. In the overall population, normal-
ization of the serum CRP concentration and ESR was
demonstrated in both the mavrilimumab treatment group
and the golimumab treatment group. At week 24, the
geometric mean serum CRP concentrations were 4.6 mg/
liter in the mavrilimumab-treated patients and 4.4 mg/liter
in the golimumab-treated patients. The geometric mean
ESR values were 23.4 mm/hour in the mavrilimumab-trea-
ted patients and 22.4 mm/hour in those treated with
golimumab. Serum CRP concentrations and the ESR over
time, in both the anti-TNF–IR and DMARD-IR popula-
tions, are provided in Figures 4A–D. In the anti-TNF–IR
population, treatment with mavrilimumab resulted in a sus-
tained decrease in the geometric mean serum CRP concen-
tration up to 24 weeks. In contrast, after an initial
reduction in concentration, the geometric mean serum
CRP concentrations increased to the values observed at
baseline or above baseline in patients receiving golimumab.
In the same anti-TNF–IR population, the geometric mean
serum ESR declined after both treatments, but started to
increase toward baseline values at later time points, partic-
ularly in the golimumab-treated patients. For patients in
the DMARD-IR population, treatment with either mavrili-
mumab or golimumab resulted in a decrease from baseline
in the geometric mean CRP concentrations and ESR.
Immunogenicity. The overall incidence of anti-
drug antibodies in the mavrilimumab-treated patients
with available immunogenicity data was 3.1% (2 of 64
patients; 1 in the DMARD-IR stratum and 1 in the anti-
TNF–IR stratum).
Figure 3. Response to mavrilimumab compared to golimumab over 24 weeks of treatment in patients with a history of inadequate response to dis-
ease-modifying antirheumatic drugs. Responses were measured based on the percentage of patients with response according to the American College
of Rheumatology criteria for 20% improvement (ACR20), 50% improvement, and 70% improvement (A), the percentage of patients with a Disease
Activity Score in 28 joints using C-reactive protein level (DAS28-CRP) of <2.6 (B), the percentage of patients with a score improvement of >0.22 on
the Health Assessment Questionnaire (HAQ) disability index (DI) (C), and the percentage of patients with a DAS28-CRP of <3.2 (D). Results are
shown as the mean  SEM.
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Safety. Treatment-emergent AEs (TEAEs) in the
overall population are summarized in Table 2, including
the most common TEAEs occurring in ≥3% of patients
and any treatment-emergent SAEs (TESAEs). Two
TESAEs were considered by the investigators to be
related to the study treatment. Both of these events,
Pneumocystis jirovecii pneumonia and “lung disorder”
(Medical Dictionary for Regulatory Activities preferred
term), were reported in the golimumab treatment
group. P jirovecii pneumonia, observed in a 69-year-old
male patient, was classified as severe and developed 8
days after administration of the tenth golimumab dose.
Golimumab was withdrawn, and the patient recovered,
with sequelae. The “lung disorder” was observed in a
patient who presented with lung abnormalities detected
on a chest radiograph at week 24 (end of treatment
visit). Analysis of the subsequent biopsy sample raised
suspicion of a diagnosis of “granulomatous process—
possible sarcoidosis.”
No deaths were reported in either treatment
group. Moreover, no significant safety signals, including
those related to pulmonary events, were identified dur-
ing the study (pulmonary function test results are shown
in Supplementary Table 1, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.40323/abstract).
DISCUSSION
This phase IIb study was designed to evaluate
the clinical effects and tolerability of the anti–GM-
CSFRa monoclonal antibody mavrilimumab in a mixed
population of biologic agent–naive and biologic agent–
experienced patients with active RA. It was planned to
support the design and potential progression of mavrili-
mumab to phase III development, which has yet to be
initiated. It was not powered to provide a direct com-
parison of mavrilimumab and golimumab.
The selection of the mavrilimumab dosage of
100 mg every other week for this study was based
on efficacy, safety, pharmacokinetic, and pharmacody-
namic data from the phase IIa study (9), in which it
was the highest dosage evaluated. In addition, the
benefit:risk ratio of higher dosages of mavrilimumab
was yet to be proven. However, since the initiation
of the current study, the phase IIb study (EARTH
EXPLORER 1) demonstrated that a mavrilimumab
dosage of 150 mg every other week was more
Figure 4. Adjusted geometric mean C-reactive protein (CRP) levels and adjusted geometric mean erythrocyte sedimentation rate (ESR) over time
in patients with a history of an inadequate response to anti–tumor necrosis factor agents (A and B) and patients with an inadequate response to
disease-modifying antirheumatic drugs (C and D). Results are shown as the mean  SEM.
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efficacious than 100 mg every other week in patients
with a history of DMARD-IR (11).
In the overall population, the efficacy of both
mavrilimumab (100 mg every other week) and goli-
mumab (50 mg every 4 weeks) was demonstrated, result-
ing in improved disease-related physical function.
However, the overall study population was heteroge-
neous in terms of medication history (0, 1, or 2 anti-TNF
failures). Therefore, it is important to interpret these
data with caution. The efficacy of mavrilimumab and
golimumab differed between the anti-TNF–IR and
DMARD-IR populations. In the DMARD-IR group,
golimumab yielded numerically higher response rates
compared with mavrilumab. Although the current results
with regard to the efficacy of mavrilimumab are consis-
tent with those previously reported by Burmester et al
(11), evidence from that same study indicated that the
higher dosage of 150 mg every other week had greater
efficacy; therefore, a mavrilimumab dosage of 100 mg
every other week may be suboptimal for clinical efficacy.
However, despite the suboptimal dosage used in this
study, mavrilimumab demonstrated efficacy that was
similar to that of golimumab in the anti-TNF–IR popula-
tion. The individual DMARD-IR and anti-TNF–IR
strata each had a greater degree of homogeneity, but the
relatively low numbers of patients per stratum and treat-
ment group limit the interpretability and generalizability
of the results. Therefore, larger studies are required to
fully evaluate whether a second anti-TNF agent is effica-
cious in an anti-TNF–IR population, and to determine the
optimal mavrilimumab dosage for the same population.
Although there are limited data available, sev-
eral studies have suggested that switching to a different
anti-TNF agent may be associated with clinical benefit
in patients with RA (28–30). Alternatively, therapies
with a different mechanism of action may prove to be
an effective treatment option. To our knowledge, no
randomized controlled study has compared the efficacy
of an anti-TNF agent with that of an experimental
non–TNF antagonist agent in patients with a history of
anti-TNF–IR. We have noted that studies have been
conducted in patients with a history of DMARD-IR
and in patients who have never received treatment with
a biologic agent.
Subgroup analysis of the ACR20 response rate
and DAS28-CRP at week 24 by geographic region
demonstrated higher response rates both with
mavrilimumab and with golimumab in patients from
South America compared with those from Europe. How-
ever, the importance of this observation remains to be
determined. These regional variations may be observed
to a greater extent in the anti-TNF–IR population than
in the DMARD-IR population, since the percentage of
patients with a history of anti-TNF–IR was higher among
those recruited at sites in South America. Interestingly,
the ACR response rates observed in patients both from
South America and from Europe in the current study
were substantially higher than those previously reported
in the phase III golimumab (GO-AFTER) study, in
which a similar cohort of patients was evaluated (30).
For example, in the current study, the ACR20 response
rates at week 24 among patients in the anti-TNF–IR
stratum who were randomized to receive golimumab 50
mg every 4 weeks were 81.2% in those from South
America and 43.8% in those from Europe. In contrast,
the ACR20 response rate reported in patients receiving
golimumab 50 mg every 4 weeks and concomitant
DMARDs in the total GO-AFTER study population
was 34.0% (30).
Individual biomarkers (serum CRP concentra-
tions and ESR) were decreased in both treatment groups
by week 24. However, the observed reduction in the
Table 2. TEAEs occurring in ≥3% of patients in either treatment
group, and TESAEs in the overall population
Mavrilimumab
100 mg every
other week
(n = 70)
Golimumab
50 mg every
4 weeks
(n = 68)
Any TEAE, no. (%) reporting
≥1 event
36 (51.4) 29 (42.6)
TEAEs in ≥3% of patients in
any group, no. (%)
Headache 3 (4.3) 2 (2.9)
Hepatic enzyme levels increased* 3 (4.3) 2 (2.9)
Hypertension 3 (4.3) 1 (1.5)
Nasopharyngitits 4 (5.7) 1 (1.5)
Upper respiratory tract infection 3 (4.3) 2 (2.9)
Viral upper respiratory tract
infection
3 (4.3) 2 (2.9)
TEAEs considered by investigators to
be related to the study drug,
no. (%) reporting ≥1 event
12 (17.1) 11 (16.2)
TEAEs resulting in permanent
discontinuation of the study drug,
no. (%) reporting ≥1 event
3 (4.3) 1 (1.5)
TEAEs resulting in interruption of
the study drug, no. (%) reporting
≥1 event
7 (10.0) 4 (5.9)
TESAEs, no. (%)
Gastroduodenitis 0 (0.0) 1 (1.5)
Hepatic enzyme levels increased* 0 (0.0) 1 (1.5)
Lung disorder† 0 (0.0) 1 (1.5)
Parathyroid tumor, benign 1 (1.4) 0 (0.0)
Peptic ulcer 0 (0.0) 1 (1.5)
Pneumocystis jirovecii pneumonia† 0 (0.0) 1 (1.5)
Vertebrobasilar insufficiency 1 (1.4) 0 (0.0)
* Investigator-reported treatment-emergent adverse event (TEAE)
(i.e., there was no defined threshold).
† Treatment-emergent serious adverse event (TESAE) considered by
the investigators to be related to the study drug.
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CRP level with golimumab treatment appeared to be
transient in patients within the anti-TNF–IR stratum,
with concentrations returning to baseline values by week
16. We have not found any studies in the anti-TNF–IR
RA population in which the CRP data have been pre-
sented in a manner similar to that in our study. One
study showed that switching to rituximab provided
greater clinical benefit than switching to a second TNF
inhibitor in patients with RA in whom treatment with a
TNF inhibitor had previously failed (29). In that study,
the patients’ clinical characteristics were measured 6
months after study initiation. At the 6-month time point,
there was no difference in the CRP levels between the
rituximab group and the alternative TNF antagonist
group. However, the DAS28-CRP and ESR were signifi-
cantly lower in the rituximab group than in the alterna-
tive TNF antagonist group (29).
Mavrilimumab and golimumab were generally well
tolerated in the present study. The percentage of patients
experiencing any TEAE was higher in the mavrilimumab
treatment group (51.4% versus 42.6% in the golimumab
treatment group). However, the majority of TEAEs were
mild and not considered to be related to the study drug.
The incidence of TESAEs and the incidence of TEAEs
leading to drug discontinuation were low, and no labora-
tory abnormality signals were observed with mavrili-
mumab. No pulmonary safety signals were identified in
the patients following the adjudication of lung function
abnormalities and pulmonary AEs by independent
experts. Notably, following treatment with mavrilimumab,
no serious pulmonary TEAEs and no suspected or con-
firmed cases of pulmonary alveolar proteinosis were iden-
tified. Overall, the safety profiles of mavrilimumab and
golimumab observed in this study were similar to those
reported in previous studies (9,10,31).
The study was limited by not being statistically
powered to directly compare the efficacy of mavrilimumab
and golimumab. In addition, the population was heteroge-
neous. Although stratification allowed analysis of more
homogeneous populations, the relatively low numbers of
patients per stratum and per treatment group limited the
interpretability and generalizability of the results. However,
the strength of the study lies in its novel design. Because of
the inclusion of an active comparator as a reference arm
and a mixed population of patients with or without prior
exposure to a biologic agent, this study offers an effective
approach to investigating new biologic agents in a manner
that reflects the current treatment landscape. Any new drug
for the treatment of RAwould enter a field of biologics and
would be compared to other drugs rather than to placebo.
In summary, mavrilimumab at a dosage of 100
mg every other week was efficacious and well-tolerated
both in patients with a history of DMARD-IR and
in patients with a history of anti-TNF–IR. Recently
published data demonstrated that administration of
mavrilimumab at a dosage of 150 mg every other week
achieved greater efficacy than a dosage of 100 mg every
other week in patients with DMARD-IR (10), suggest-
ing that a higher dosage of mavrilimumab (at least 150
mg every other week) may be expected to achieve
improved benefit in RA patients with a history of an
inadequate response to anti-TNF agents. However, this
hypothesis requires confirmation. In summary, these
data demonstrate that meaningful benefits can be
obtained by targeting the GM-CSF receptor in a broad
population of patients with active RA.
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